• Contact Us
  • Careers
  • Facebook
  • Instagram
  • Twitter
  • LinkedIn
Travere Therapeutics
  • Our Company
    • Who We Are
    • Leadership & Board
    • Patient Advocacy
    • Diversity, Equity, Inclusion & Belonging
    • Grant Programs
      • ISR Grants
      • Med Ed Grants
    • Contact Us
    • Careers
    • News
  • Our Science
    • Our Pipeline
      • Sparsentan for IgAN
      • Sparsentan for FSGS
      • Chenodeoxycholic Acid (CDCA) Program
      • Pegtibatinase
      • Alagille Syndrome Collaboration
    • Therapeutic Areas
      • IgA Nephropathy (IgAN)
      • Focal Segmental Glomerulosclerosis (FSGS)
      • Classical Homocystinuria (HCU)
      • Alagille Syndrome (ALGS)
      • Bile Acid Synthesis Disorders (BASD)
      • Cerebrotendinous Xanthomatosis (CTX)
      • Cystinuria
      • Peroxisome Biogenesis Disorder-Zellweger Spectrum Disorder (PBD-ZSD)
    • Clinical Trials
    • Expanded Access
    • Diagnostic Testing Programs
  • Our Therapies
  • Rare Life
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Leadership & Board
    • Governance Documents
    • SEC Filings
    • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • Investor Q&As
    • Contact Us
↑ Return to Top
Travere_Logo_White
  • Facebook
  • Instagram
  • Twitter
  • LinkedIn
  • Terms & Conditions
  • Privacy
  • Your Privacy Choices

© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.